torsdag 5 maj 2011
söndag 1 maj 2011
Studies have demonstrated that angiotensin II has been involved in immune and inflammatory responses which might contribute to the pathogenesis of immune-mediated diseases. Recent evidence suggests that oxidative stress may play a role in myocarditis. Here, we investigated whether olmesartan, an AT(1)R antagonist protects against experimental autoimmune myocarditis (EAM) by suppression of oxidative stress, endoplasmic reticulum (ER) stress and inflammatory cytokines.
EAM was induced in Lewis rats by immunization with porcine cardiac myosin, were divided into two groups and treated with either olmesartan (10 mg/kg/day) or vehicle for a period of 21 days. Myocardial functional parameters measured by hemodynamic and echocardiographic analyses were significantly improved by the treatment with olmesartan compared with those of vehicle-treated rats. Treatment with olmesartan attenuated the myocardial mRNA expressions of proinflammatory cytokines, [Interleukin (IL)-1β, monocyte chemoattractant protein-1, tumor necrosis factor-α and interferon-γ)] and the protein expression of tumor necrosis factor-α compared with that of vehicle-treated rats. Myocardial protein expressions of AT(1)R, NADPH oxidase subunits (p47phox, p67phox, gp91phox) and the expression of markers of oxidative stress (3-nitrotyrosine and 4-hydroxy-2-nonenal), and the cardiac apoptosis were also significantly decreased by the treatment with olmesartan compared with those of vehicle-treated rats. Furthermore, olmesartan treatment down-regulated the myocardial expressions of glucose regulated protein-78, growth arrest and DNA damage-inducible gene, caspase-12, phospho-p38 mitogen-activated protein kinase (MAPK) and phospho-JNK. These findings suggest that olmesartan protects against EAM in rats, at least in part via suppression of oxidative stress, ER stress and inflammatory cytokines.
- [PubMed - in process]
- PMCID: PMC3048845
ARB olmesartaani heikensi inflammatoristen sytokiinien ilmenemää ( IL1beeta, MCP-1, TNF-alfa, IFN-gamma).
Geenitutkimuksen sektorilla on tehty uusia löytöä. Löydetyillä uusilla geeneillä on osuutta myös autoimmuunitaudeissa kuten reumassa ja diabeteksessa. Uutta endoskooppitekniikka on kehitelty. Mitään erityisempiä suuria uusia edistysaskeleita ei ole kuitenkaan tapahtunut stitten aiempien symposiumien.
The programme provided an update on the current state of the art in the field of Coeliac Disease.
Progress has been made in identifying new genes that increase susceptibility for Celiac Disease. However the latest discovered genes give a small extra contribution, it is interesting that genes are found that also a role play at other auto-immune diseases such as rheumatoid arthritis and diabetes.
A large number of abstracts dealt with serologic tests for Coeliac Disease. The use of these tests makes it easy to perform large scale epidemiologic studies.
New endoscopic imaging techniques also show their advantages in the detection of celiac disease and its complications.
Studies on new therapeutic strategies for Celiac Disease are in progress but no major breakthroughs were shown.
For the abstracts click here.
Next symposia: There has been decided to set up a foundation for the organization of future symposia. In this foundation the organizers of the symposia in the past and the future organizers will join their strengths.
The three coming meetings are scheduled as follows:
ICDS2011 June 20-22, 2011 Oslo, Norway
ICDS2013 Chicago, USA
ICDS2015 Praque, Tsjech Republic
Coeliac disease : proceedings of the Xth International Symposium on coeliac disease
|Author:||N Cerf-Bensussan; et al|
|Publisher:||Montrouge : John Libbey Eurotext , 2003.|
|Edition/Format:||Book : English|
Tässä konferenssissa on julkaistu edistysaskeleita mm MMP- entsyymien tutkimus alueelta.
Kts blogiani metalloproteinaasit
(not yet rated) 0 with reviews - Be the first.